Nan H, Han L, Ma J, Yang C, Su R, He J. STX3 represses the stability of the tumor suppressor PTEN to activate the PI3K-Akt-mTOR signaling and promotes the growth of breast cancer cells. Biochim Biophys Acta Mol Basis Dis. 2018;1864:1684-1692 pubmed 出版商

Oblinger J, Burns S, Huang J, Pan L, Ren Y, Shen R, et al. Overexpression of eIF4F components in meningiomas and suppression of meningioma cell growth by inhibiting translation initiation. Exp Neurol. 2018;299:299-307 pubmed 出版商

Sinha S, Thomas D, Chan S, Gao Y, Brunen D, Torabi D, et al. Systematic discovery of mutation-specific synthetic lethals by mining pan-cancer human primary tumor data. Nat Commun. 2017;8:15580 pubmed 出版商

Ip W, Hoshi N, Shouval D, Snapper S, Medzhitov R. Anti-inflammatory effect of IL-10 mediated by metabolic reprogramming of macrophages. Science. 2017;356:513-519 pubmed 出版商

Gupta A, Anjomani Virmouni S, Koundouros N, Dimitriadi M, Choo Wing R, Valle A, et al. PARK2 Depletion Connects Energy and Oxidative Stress to PI3K/Akt Activation via PTEN S-Nitrosylation. Mol Cell. 2017;65:999-1013.e7 pubmed 出版商

Merhi A, Delree P, Marini A. The metabolic waste ammonium regulates mTORC2 and mTORC1 signaling. Sci Rep. 2017;7:44602 pubmed 出版商

Kissing S, Rudnik S, Damme M, Lüllmann Rauch R, Ichihara A, Kornak U, et al. Disruption of the vacuolar-type H+-ATPase complex in liver causes MTORC1-independent accumulation of autophagic vacuoles and lysosomes. Autophagy. 2017;13:670-685 pubmed 出版商

Kang Y, Balter B, Csizmadia E, Haas B, Sharma H, Bronson R, et al. Contribution of classical end-joining to PTEN inactivation in p53-mediated glioblastoma formation and drug-resistant survival. Nat Commun. 2017;8:14013 pubmed 出版商

Rahman A, Haugh J. Kinetic Modeling and Analysis of the Akt/Mechanistic Target of Rapamycin Complex 1 (mTORC1) Signaling Axis Reveals Cooperative, Feedforward Regulation. J Biol Chem. 2017;292:2866-2872 pubmed 出版商

Maynard J, Emmas S, Blé F, Barjat H, Lawrie E, Hancox U, et al. The use of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG PET) as a pathway-specific biomarker with AZD8186, a PI3K?/? inhibitor. EJNMMI Res. 2016;6:62 pubmed 出版商

Diez H, Benitez M, Fernandez S, Torres Aleman I, Garrido J, Wandosell F. Class I PI3-kinase or Akt inhibition do not impair axonal polarization, but slow down axonal elongation. Biochim Biophys Acta. 2016;1863:2574-2583 pubmed 出版商

Hakim S, Dyson J, Feeney S, Davies E, Sriratana A, Koenig M, et al. Inpp5e suppresses polycystic kidney disease via inhibition of PI3K/Akt-dependent mTORC1 signaling. Hum Mol Genet. 2016;25:2295-2313 pubmed

Singh A, Joshi S, Zulcic M, Alcaraz M, GARLICH J, Morales G, et al. PI-3K Inhibitors Preferentially Target CD15+ Cancer Stem Cell Population in SHH Driven Medulloblastoma. PLoS ONE. 2016;11:e0150836 pubmed 出版商

Nemazanyy I, Montagnac G, Russell R, Morzyglod L, Burnol A, Guan K, et al. Class III PI3K regulates organismal glucose homeostasis by providing negative feedback on hepatic insulin signalling. Nat Commun. 2015;6:8283 pubmed 出版商

Heinemann A, Cullinane C, De Paoli Iseppi R, Wilmott J, Gunatilake D, Madore J, et al. Combining BET and HDAC inhibitors synergistically induces apoptosis of melanoma and suppresses AKT and YAP signaling. Oncotarget. 2015;6:21507-21 pubmed

Gross S, Rotwein P. Akt signaling dynamics in individual cells. J Cell Sci. 2015;128:2509-19 pubmed 出版商

Sadok A, McCarthy A, Caldwell J, Collins I, Garrett M, Yeo M, et al. Rho kinase inhibitors block melanoma cell migration and inhibit metastasis. Cancer Res. 2015;75:2272-84 pubmed 出版商

Hausmann S, Brandt E, Köchel C, Einsele H, Bargou R, Seggewiss Bernhardt R, et al. Loss of serum and glucocorticoid-regulated kinase 3 (SGK3) does not affect proliferation and survival of multiple myeloma cell lines. PLoS ONE. 2015;10:e0122689 pubmed 出版商

Panneerselvam J, Jin J, Shanker M, Lauderdale J, BATES J, Wang Q, et al. IL-24 inhibits lung cancer cell migration and invasion by disrupting the SDF-1/CXCR4 signaling axis. PLoS ONE. 2015;10:e0122439 pubmed 出版商

Alayev A, Berger S, Kramer M, Schwartz N, Holz M. The combination of rapamycin and resveratrol blocks autophagy and induces apoptosis in breast cancer cells. J Cell Biochem. 2015;116:450-7 pubmed 出版商

Godde N, Sheridan J, Smith L, Pearson H, Britt K, Galea R, et al. Scribble modulates the MAPK/Fra1 pathway to disrupt luminal and ductal integrity and suppress tumour formation in the mammary gland. PLoS Genet. 2014;10:e1004323 pubmed 出版商

Paugh B, Zhu X, Qu C, Endersby R, Diaz A, Zhang J, et al. Novel oncogenic PDGFRA mutations in pediatric high-grade gliomas. Cancer Res. 2013;73:6219-29 pubmed 出版商

BENTLEY C, Jurinka S, Kljavin N, Vartanian S, Ramani S, Gonzalez L, et al. A requirement for wild-type Ras isoforms in mutant KRas-driven signalling and transformation. Biochem J. 2013;452:313-20 pubmed 出版商

Chen M, Nowak D, Narula N, Robinson B, Watrud K, Ambrico A, et al. The nuclear transport receptor Importin-11 is a tumor suppressor that maintains PTEN protein. J Cell Biol. 2017;216:641-656 pubmed 出版商

Gross S, Rotwein P. Quantification of growth factor signaling and pathway cross talk by live-cell imaging. Am J Physiol Cell Physiol. 2017;312:C328-C340 pubmed 出版商

Henry W, Laszewski T, Tsang T, Beca F, Beck A, McAllister S, et al. Aspirin Suppresses Growth in PI3K-Mutant Breast Cancer by Activating AMPK and Inhibiting mTORC1 Signaling. Cancer Res. 2017;77:790-801 pubmed 出版商

Kang J, Kusnadi E, Ogden A, Hicks R, Bammert L, Kutay U, et al. Amino acid-dependent signaling via S6K1 and MYC is essential for regulation of rDNA transcription. Oncotarget. 2016;7:48887-48904 pubmed 出版商

Holler M, Grottke A, Mueck K, Manes J, Jücker M, Rodemann H, et al. Dual Targeting of Akt and mTORC1 Impairs Repair of DNA Double-Strand Breaks and Increases Radiation Sensitivity of Human Tumor Cells. PLoS ONE. 2016;11:e0154745 pubmed 出版商

Carlino M, Fung C, Shahheydari H, Todd J, Boyd S, Irvine M, et al. Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients. Clin Cancer Res. 2015;21:98-105 pubmed 出版商

Theiss A, Chafin D, Bauer D, Grogan T, Baird G. Immunohistochemistry of colorectal cancer biomarker phosphorylation requires controlled tissue fixation. PLoS ONE. 2014;9:e113608 pubmed 出版商

Liu P, Begley M, Michowski W, Inuzuka H, Ginzberg M, Gao D, et al. Cell-cycle-regulated activation of Akt kinase by phosphorylation at its carboxyl terminus. Nature. 2014;508:541-5 pubmed 出版商

Wattenberg M, Kwilas A, Gameiro S, Dicker A, Hodge J. Expanding the use of monoclonal antibody therapy of cancer by using ionising radiation to upregulate antibody targets. Br J Cancer. 2014;110:1472-80 pubmed 出版商

Jordan N, Dutkowski C, Barrow D, Mottram H, Hutcheson I, Nicholson R, et al. Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro. Breast Cancer Res. 2014;16:R12 pubmed 出版商

Li J, Davies B, Han S, Zhou M, Bai Y, Zhang J, et al. The AKT inhibitor AZD5363 is selectively active in PI3KCA mutant gastric cancer, and sensitizes a patient-derived gastric cancer xenograft model with PTEN loss to Taxotere. J Transl Med. 2013;11:241 pubmed 出版商

Radhakrishnan P, Baraneedharan U, Veluchamy S, Dhandapani M, Pinto D, Thiyagarajan S, et al. Inhibition of rapamycin-induced AKT activation elicits differential antitumor response in head and neck cancers. Cancer Res. 2013;73:1118-27 pubmed 出版商

Chafin D, Theiss A, Roberts E, Borlee G, Otter M, Baird G. Rapid two-temperature formalin fixation. PLoS ONE. 2013;8:e54138 pubmed 出版商

Yi K, Axtmayer J, Gustin J, Rajpurohit A, Lauring J. Functional analysis of non-hotspot AKT1 mutants found in human breast cancers identifies novel driver mutations: implications for personalized medicine. Oncotarget. 2013;4:29-34 pubmed

Jozefczuk J, Kashofer K, Ummanni R, Henjes F, Rehman S, Geenen S, et al. A Systems Biology Approach to Deciphering the Etiology of Steatosis Employing Patient-Derived Dermal Fibroblasts and iPS Cells. Front Physiol. 2012;3:339 pubmed 出版商

Chow B, Chew E, Zhao C, Bathgate R, Hewitson T, Samuel C. Relaxin signals through a RXFP1-pERK-nNOS-NO-cGMP-dependent pathway to up-regulate matrix metalloproteinases: the additional involvement of iNOS. PLoS ONE. 2012;7:e42714 pubmed 出版商

Faber A, Corcoran R, Ebi H, Sequist L, Waltman B, Chung E, et al. BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors. Cancer Discov. 2011;1:352-65 pubmed 出版商

Andersen J, Sathyanarayanan S, Di Bacco A, Chi A, Zhang T, Chen A, et al. Pathway-based identification of biomarkers for targeted therapeutics: personalized oncology with PI3K pathway inhibitors. Sci Transl Med. 2010;2:43ra55 pubmed 出版商

Thomson D, Hancock C, Evanson B, Kenney S, Malan B, Mongillo A, et al. Skeletal muscle dysfunction in muscle-specific LKB1 knockout mice. J Appl Physiol (1985). 2010;108:1775-85 pubmed 出版商